Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Medarex Inc.
2009 · Acquisition/Merger · $2.4B · Complete
Announcement Sentiment
63
Positive
Outcome Score
92
Worked — the deal delivered on its rationale.
BMS acquired Medarex for $2.4B as part of String of Pearls strategy.
Did it work? Outcome assessment
BMS / Medarex: Achieved Stated Rationale (Score: 96/100)
Strategic verdict
Achieved Stated Rationale
Assessment window: 10yr post-close.
Key facts
- Announced Jul 22, 2009
- Closed Sep 01, 2009
- Deal value $2.4B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals